Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Head and Neck
• Lung
• Lymphoma
• Melanoma
• Pancreatic
• Prostate
• Solid Tumors

 

Bladder

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• Dato-DXd +/- Durvalumab vs. Investigator’s choice in Triple Neg Breast Ca

  A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
  

  ---

• Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients

  Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
  

  ---

• Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant

  A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
  

  ---

• Phase III Study Comparing Gedatolisib + Palbociclib & Fulvestrant to SOC treatments in Breast Ca

  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
  

  ---

• A Study of treatments in Her2+ first line metastatic breast cancer

  A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
  

  ---

Colon

• Phase 3 study of MRTX849 + Cetuximab vs. Chemo in patients with colon cancer w/KRAS G12C mutation

  A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
  

  ---

• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

  Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
  

  ---

• Tucatini with Traztuzumab and mFOLFOX6 vs mFOLFOX6 w/or w/o Cetuximab or Bevacizumab for colorectal

  An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
  

  ---

• Phase 3 study of MK4280A vs SOC in colorectal cancer

  A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer
  

  ---

Gastrointestinal

• TT-00420 in Patients with Advanced Cholangiocarcinoma

  A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma
  

  ---

• Phase 3 Study of INCMGA00012 in Anal Cancer

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

Head and Neck

• NGM707 vs. NGM707 and Pembrolizumab in Solid Tumor Malignancies

  A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101)
  

  ---

Lung

• AB122 + AB154 vs. Pembrolizumab in 1st line PDL1- High NSCLC

  A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• NGM707 vs. NGM707 and Pembrolizumab in Solid Tumor Malignancies

  A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101)
  

  ---

• Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC

  Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC
  

  ---

• Multiple Therapies according to biomarker status in patients with Lung Cancer

  A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer
  

  ---

• Screening Study to determine biomarker status for patients with malignant tumors

  Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors
  

  ---

• Phase III study of osimertinib as monotherapy or in combination w/chemo vs SOC patients w/NSCLC

  A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
  

  ---

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

• Phase 3 Study of Selpercatinib in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• A Phase 3 study of Adjuvant Selpercatinib in lung cancer

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

Lymphoma

• Stage 3 study of Tazemetostat/placebo + Lenalidomide and Rituximab in Patients with FL

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)
  

  ---

• Phase 3 Study of Acalabrutinib in Untreated Diffuse Large B-Cell Lymphoma

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

Melanoma

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

Pancreatic

• BI 907872 in locally advanced/metastatic disease with MDM2 amplified, TP53 wild-type solid tumors

  A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.
  

  ---

Prostate

• A Phase 3 study Abiraterone + Capivasertib/Placebo in Prostate Cancer

  A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
  

  ---

Solid Tumors

• BI 907872 in locally advanced/metastatic disease with MDM2 amplified, TP53 wild-type solid tumors

  A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.
  

  ---

• Trial of Nab-Sirolimus for patients with malignant solid tumors with TSC1 or TSC2 alterations

  A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
  

  ---

• A Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

  A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (NC318-01)
  

  ---

• A Phase 2 study of Seribantumab in Patients with Solid Tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---